We evaluated PC-related treatment patterns and associated health care resource use among patients with metastatic PC in the United Kingdom and France. This study provides new, detailed information for patients with metastatic PC in real-world settings in 2 European countries. A small proportion of patients received >1 line of systemic therapy for metastatic disease, which is likely due to the aggressiveness of this disease and the lack of effective therapeutic options.